The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke
Open accessAbstract
BACKGROUND: Whether closure of a patent foramen ovale reduces the risk of recurrence of ischemic stroke in patients who have had a cryptogenic ischemic stroke is unknown. METHODS: In a multicenter, randomized, open-label trial, with blinded adjudication of end-point events, we randomly assigned patients 18 to 60 years of age who had a patent foramen ovale (PFO) and had had a cryptogenic ischemic stroke to undergo closure of the PFO (PFO closure group) or to receive medical therapy alone (aspirin, warfarin, clopidogrel, or aspirin combined with extended-release dipyridamole; medical-therapy group). The primary efficacy end point was a composite of recurrent nonfatal ischemic stroke, fatal ischemic stroke, or early death after randomization. The results of the analysis of the primary outcome from the original trial period have been reported previously; the current analysis of data from the extended follow-up period was considered to be exploratory. RESULTS: We enrolled 980 patients (mean age, 45.9 years) at 69 sites. Patients were followed for a median of 5.9 years. Treatment exposure in the two groups was unequal (3141 patient-years in the PFO closure group vs. 2669 patient-years in the medical-therapy group), owing to a higher dropout rate in the medical-therapy group. In the intention-to-treat population, recurrent ischemic stroke occurred in 18 patients in the PFO closure group and in 28 patients in the medical-therapy group, resulting in rates of 0.58 events per 100 patient-years and 1.07 events per 100 patient-years, respectively (hazard ratio with PFO closure vs. medical therapy, 0.55; 95% confidence interval [CI], 0.31 to 0.999; P=0.046 by the log-rank test). Recurrent ischemic stroke of undetermined cause occurred in 10 patients in the PFO closure group and in 23 patients in the medical-therapy group (hazard ratio, 0.38; 95% CI, 0.18 to 0.79; P=0.007). Venous thromboembolism (which comprised events of pulmonary embolism and deep-vein thrombosis) was more common in the PFO closure group than in the medical-therapy group. CONCLUSIONS: Among adults who had had a cryptogenic ischemic stroke, closure of a PFO was associated with a lower rate of recurrent ischemic strokes than medical therapy alone during extended follow-up. (Funded by St. Jude Medical; RESPECT ClinicalTrials.gov number, NCT00465270 .).
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Adams, H. P., Bendixen, B. H., Kappelle, L. J., Biller, J., Love, B. B., Gordon, D. L., & Marsh, E. E. (1993) · Stroke · doi:10.1161/01.str.24.1.35 · Cited by 12,335
Transcatheter or Surgical Aortic-Valve Replacement in Intermediate-Risk Patients
Leon, M. B., Smith, C. R., Mack, M. J., Makkar, R. R., Svensson, L. G., Kodali, S. K., Thourani, V. H., Tuzcu, E. M., Miller, D. C., Herrmann, H. C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1514616 · Cited by 5,053
Antithrombotic Therapy for VTE Disease
Kearon, C., Akl, E. A., Ornelas, J., Blaivas, A., Jimenez, D., Bounameaux, H., Huisman, M., King, C. S., Morris, T. A., Sood, N., et al. (2016) · Chest · doi:10.1016/j.chest.2015.11.026 · Cited by 4,830
Sacco, R. L., Adams, R., Albers, G., Alberts, M. J., Benavente, O., Furie, K., Goldstein, L. B., Gorelick, P., Halperin, J., Harbaugh, R., et al. (2006) · Stroke · doi:10.1161/01.str.0000199147.30016.74 · Cited by 1,873
Embolic strokes of undetermined source: the case for a new clinical construct
Hart, R. G., Diener, H.-C., Coutts, S. B., Easton, J. D., Granger, C. B., O'Donnell, M. J., Sacco, R. L., & Connolly, S. J. (2014) · The Lancet Neurology · doi:10.1016/s1474-4422(13)70310-7 · Cited by 1,681
Closure or Medical Therapy for Cryptogenic Stroke with Patent Foramen Ovale
Furlan, A. J., Reisman, M., Massaro, J., Mauri, L., Adams, H., Albers, G. W., Felberg, R., Herrmann, H., Kar, S., Landzberg, M., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1009639 · Cited by 1,060
Closure of Patent Foramen Ovale versus Medical Therapy after Cryptogenic Stroke
Carroll, J. D., Saver, J. L., Thaler, D. E., Smalling, R. W., Berry, S., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1301440 · Cited by 983
Self-citationPercutaneous Closure of Patent Foramen Ovale in Cryptogenic Embolism
Meier, B., Kalesan, B., Mattle, H. P., Khattab, A. A., Hildick-Smith, D., Dudek, D., Andersen, G., Ibrahim, R., Schuler, G., Walton, A. S., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1211716 · Cited by 920
Reddy, V. Y., Doshi, S. K., Sievert, H., Buchbinder, M., Neuzil, P., Huber, K., Halperin, J. L., & Holmes, D. (2013) · Circulation · doi:10.1161/circulationaha.112.114389 · Cited by 677
The ASCOD Phenotyping of Ischemic Stroke (Updated ASCO Phenotyping)
Amarenco, P., Bogousslavsky, J., Caplan, L. R., Donnan, G. A., Wolf, M. E., & Hennerici, M. G. (2013) · Cerebrovascular Diseases · doi:10.1159/000352050 · Cited by 397
Cited by
Powers, W. J., Rabinstein, A. A., Ackerson, T., Adeoye, O. M., Bambakidis, N. C., Becker, K., Biller, J., Brown, M., Demaerschalk, B. M., Hoh, B., et al. (2019) · Stroke · doi:10.1161/str.0000000000000211 · Cited by 7,468
Self-citationKleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Campbell, B. C. V., De Silva, D. A., Macleod, M. R., Coutts, S. B., Schwamm, L. H., Davis, S. M., & Donnan, G. A. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0118-8 · Cited by 1,750
Rivaroxaban for Stroke Prevention after Embolic Stroke of Undetermined Source
Hart, R. G., Sharma, M., Mundl, H., Kasner, S. E., Bangdiwala, S. I., Berkowitz, S. D., Swaminathan, B., Lavados, P., Wang, Y., Wang, Y., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1802686 · Cited by 1,028
Feske, S. K. (2021) · The American Journal of Medicine · doi:10.1016/j.amjmed.2021.07.027 · Cited by 822
Metadata
- Authors
- Saver, J. L., Carroll, J. D., Thaler, D. E., Smalling, R. W., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2017-09-14
- Volume
- 377
- Issue
- 11
- Pages
- 1022-1032
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2755964661
- Cited by
- 1,127
- References
- 17
- FWCI
- 97.60
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. https://app.cochat.ai/papers/10.1056/nejmoa1610057
- The paper
- Saver, J. L., Carroll, J. D., Thaler, D. E., Smalling, R. W., MacDonald, L. A., Marks, D. S., & Tirschwell, D. L. (2017). Long-Term Outcomes of Patent Foramen Ovale Closure or Medical Therapy after Stroke. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1610057
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.